Add-on Acquisition • Life Science

Aceragen Acquires Arrevus

On October 28, 2021, Aceragen acquired life science company Arrevus

Acquisition Context

This is Aceragen’s 1st transaction in the Life Science sector.
This is Aceragen’s 1st transaction in the United States.
This is Aceragen’s 1st transaction in North Carolina.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	October 28, 2021
Target	Arrevus
Sector	Life Science
Buyer(s)	Aceragen
Deal Type	Add-on Acquisition

Target Company

Arrevus

Durham, North Carolina, United States

Arrevus is a biotechnology company whose mission is to eliminate the threat of antibiotic resistance and improve treatment outcomes for serious infectious diseases. The company is applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs). Arrevus was formed in 2015 and is based in Durham, North Carolina.

Explore More Deals

Browse All 215,130 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Aceragen

Research Triangle Park, North Carolina, United States

Category	Company
Sector	Life Science

DESCRIPTION

Aceragen is a biopharmaceutical company developing innovative therapeutics for rare and orphan diseases. The Company is advancing ACG-801 (rhAC) as an investigational enzyme replacement therapy for the treatment of patients with Farber disease and potentially other diseases associated with the dysregulation of ceramide metabolism, including cystic fibrosis. Its other development lead is ACG-721, an oral small molecule candidate for cystic fibrosis pulmonary exacerbations and related orphan infectious diseases. Aceragen is based in Research Triangle Park, North Carolina.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: North Carolina	1 of 1
Country: United States	1 of 1
Year: 2021	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - North Carolina M&A - United States M&A - 2021 M&A